NEW YORK – GeneCentric Therapeutics and the Netherlands-based Erasmus University Medical Center said on Thursday that they are collaborating to identify RNA-based drug response markers and novel, targeted therapies for treating non-muscle invasive bladder cancer (NMIBC).
Under the research collaboration, North Carolina-based GeneCentric will use its Bladder Cancer Subtype Profiler tool to characterize the tumor, the patient's immune biology, and the tumor microenviroment. It may also use other novel assays to predict disease progression and drug response in these patients.